|Growth in CHF (in %)||14.7%||9.3%||8.2%|
|Gross margin (in %)||78.2%||78.7%||79.0%|
|EBITDA margin (in %)||28.6%||29.5%||30.3%|
|EBIT margin (in %)||24.7%||25.6%||26.3%|
The following analysts / banks have contributed to this consensus:
Note: For the year 2017, the company will benefit from two acquisition effects: 1) Full consolidation of Medentiak GmbH, Germany (51% ownership) and 2) acquisiton of equinox, India. These effects and currency fluctuations are included in the revenue line.
1 This I/B/E/S consensus data represent all available analyst reports which have been issued 2 or 200 days ago. This consensus has been issued for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Straumann did not participate in the compilation of the estimates and it does not endorse them. The company gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.
Latest update: 21. December 2016